Mallinckrodt Plc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Mallinckrodt Plc (MNKKQ) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Mallinckrodt Plc vs Its Competitors
- TTM: Trailing 12-month revenue of 1,979M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is holding steady (-0.8% annualized vs trailing 12 months).
- Peer revenue share: Mallinckrodt Plc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
MNKKQ Sales vs. its Competitors, 2022
Mallinckrodt Plc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
For context: the Major Pharmaceutical Preparations industry grew revenue 9.1% year over year, combined, vs -12.0% for Mallinckrodt Plc. Mallinckrodt Plc's share of combined industry revenue moved from 0.12% to 0.10%, a loss of 0.02 percentage points.
Mallinckrodt Plc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Mallinckrodt Plc | No | No | No | No |
| High-Confidence Competitors (3) | - | - | - | |
| Similar Growth & Profitability (8) | 0.00 % (0 of 7) | 0.00 % (0 of 8) | 0.00 % (0 of 8) | 50.00 % (4 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
MNKKQ Stock Performance relative to its Competitors
MNKKQ Stock Performance relative to High-Confidence Competitors
MNKKQ Stock Performance relative to Similar Growth & Profitability Competitors
Mallinckrodt Plc's Competitors Named by the Company
Competitive relationships identified from Mallinckrodt Plc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Nu med Plus Inc | Company report | 85% |
| Ovid Therapeutics Inc | Company report | 85% |
| Trevena inc | Company report | 85% |
| Amneal Pharmaceuticals Inc | Company report | 85% |
| Bausch Health Companies Inc | Company report | 85% |
| Endo International Plc | Company report | 85% |
| Collegium Pharmaceutical Inc | Company report | 85% |
| Eton Pharmaceuticals Inc | Company report | 85% |
| Eagle Pharmaceuticals inc | Company report | 85% |
| Perrigo Company Plc | Company report | 85% |
| Indivior Pharmaceuticals Inc | Company report | 85% |
| Abbvie Inc | Company report | 85% |
| Viatris Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Mallinckrodt Plc's named competitors require a Commercial License.
Methodology: relationships are extracted from Mallinckrodt Plc reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.